We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Insight into Rapid Evolution of AMR in Patients Calls for Shift in Diagnostic Testing Approaches

By LabMedica International staff writers
Posted on 01 Aug 2023
Print article
Image: A study has revealed new mechanism for rapid evolution of multi-drug resistant infections in patients (Shutterstock)
Image: A study has revealed new mechanism for rapid evolution of multi-drug resistant infections in patients (Shutterstock)

A groundbreaking research study has offered novel insights into the development of antimicrobial resistance (AMR) in patients suffering from bacterial infections. This could lead to more effective preventative strategies against AMR infections in susceptible individuals. Contrary to the conventional belief that infection typically occurs due to a single strain of bacteria that develops resistance through new genetic mutations, the study suggests that patients often get co-infected by multiple clones of pathogens. In these cases, resistance arises from the selection of already resistant clones rather than new mutations.

In the study led by the University of Oxford (Oxford, UK), the researchers utilized an innovative technique to examine genetic alterations and antibiotic resistance in Pseudomonas aeruginosa, a common hospital-acquired bacterium, particularly among immunocompromised and severely ill individuals. Samples were taken from 35 patients in intensive care units across 12 European hospitals. Approximately two-thirds of the patients were found to be infected by a single strain of Pseudomonas, in some of which AMR developed due to new mutations, as traditionally believed. However, in a surprising revelation, one-third of patients were infected by multiple strains of the bacteria. It was observed that patients with mixed-strain infections exhibited a roughly 20% higher increase in resistance when exposed to antibiotic treatment compared to those with single-strain infections. The spike in resistance was primarily attributed to the selection of pre-existing resistant strains that already existed prior to antibiotic therapy.

Interestingly, the study also found that such resistance could decline rapidly under certain conditions. When samples from single-strain and mixed-strain infections were cultured without antibiotics, the growth rate of AMR strains was slower compared to non-AMR strains. This supports the idea that AMR genes carry fitness trade-offs and are negatively selected when antibiotics are absent. This effect was more pronounced in mixed strain populations, suggesting that a diverse bacterial environment could contribute to resistance loss in the absence of antibiotics.

The findings suggest that strategies focusing on controlling bacterial transmission among patients, such as improved sanitation and infection control measures, might be more effective against AMR compared to efforts to prevent new resistance mutations. This is particularly important in settings with a high infection rate, like immunocompromised individuals. Additionally, the study calls for a shift in clinical testing, emphasizing the importance of considering pathogen strain diversity instead of assuming a singular strain during infection assessments. This approach could aid in making more accurate predictions about antibiotic treatment effectiveness and improve patient outcomes, similar to the use of diversity measurements in cancer cell populations to predict chemotherapy success.

"The diagnostic methods employed for assessing antibiotic resistance in patient samples have undergone slow evolution over time, and our findings highlight the significance of developing new diagnostic approaches that facilitate the assessment of pathogen population diversity in patient samples," said Professor Craig Maclean, the lead researcher from the University of Oxford's Department of Biology.

Related Links:
University of Oxford 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.